Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Identifieur interne : 000314 ( Main/Exploration ); précédent : 000313; suivant : 000315Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Auteurs : Calvin J. Gordon [Canada] ; Egor P. Tchesnokov [Canada] ; Emma Woolner [Canada] ; Jason K. Perry [États-Unis] ; Joy Y. Feng [États-Unis] ; Danielle P. Porter [États-Unis] ; Matthias Gotte [Canada]Source :
- The Journal of biological chemistry [ 1083-351X ] ; 2020.
Abstract
Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analogue remdesivir (RDV). RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus (EBOV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain-termination is RDV's plausible mechanism of action. Here, we expressed and purified active SARS-CoV-2 RdRp composed of the non-structural proteins nsp8 and nsp12. Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA. Incorporation of RDV-TP at position i caused termination of RNA synthesis at position i+3. We obtained almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps. A unique property of RDV-TP is its high selectivity over incorporation of its natural nucleotide counterpart ATP. In this regard, the triphosphate forms of 2'-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits. Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by the distantly related Lassa virus RdRp, and termination of RNA synthesis was not observed. These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral (DAA).
DOI: 10.1074/jbc.RA120.013679
PubMed: 32284326
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000184
- to stream PubMed, to step Curation: 000184
- to stream PubMed, to step Checkpoint: 000262
- to stream Ncbi, to step Merge: 003941
- to stream Ncbi, to step Curation: 003941
- to stream Ncbi, to step Checkpoint: 003941
- to stream Main, to step Merge: 000314
- to stream Main, to step Curation: 000314
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.</title>
<author><name sortKey="Gordon, Calvin J" sort="Gordon, Calvin J" uniqKey="Gordon C" first="Calvin J" last="Gordon">Calvin J. Gordon</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Alberta</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Tchesnokov, Egor P" sort="Tchesnokov, Egor P" uniqKey="Tchesnokov E" first="Egor P" last="Tchesnokov">Egor P. Tchesnokov</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Alberta</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Woolner, Emma" sort="Woolner, Emma" uniqKey="Woolner E" first="Emma" last="Woolner">Emma Woolner</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Alberta</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Perry, Jason K" sort="Perry, Jason K" uniqKey="Perry J" first="Jason K" last="Perry">Jason K. Perry</name>
<affiliation wicri:level="1"><nlm:affiliation>Gilead Sciences, Inc, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Gilead Sciences, Inc</wicri:regionArea>
<wicri:noRegion>Inc</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Feng, Joy Y" sort="Feng, Joy Y" uniqKey="Feng J" first="Joy Y" last="Feng">Joy Y. Feng</name>
<affiliation wicri:level="1"><nlm:affiliation>Biology, Gilead Sciences, Inc., United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Biology, Gilead Sciences, Inc.</wicri:regionArea>
<wicri:noRegion>Inc.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Porter, Danielle P" sort="Porter, Danielle P" uniqKey="Porter D" first="Danielle P" last="Porter">Danielle P. Porter</name>
<affiliation wicri:level="1"><nlm:affiliation>Gilead Scienes, Inc., United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Gilead Scienes, Inc.</wicri:regionArea>
<wicri:noRegion>Inc.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gotte, Matthias" sort="Gotte, Matthias" uniqKey="Gotte M" first="Matthias" last="Gotte">Matthias Gotte</name>
<affiliation wicri:level="1"><nlm:affiliation>Medical Microbiology and Immunology, University of Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Medical Microbiology and Immunology, University of Alberta</wicri:regionArea>
<wicri:noRegion>University of Alberta</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32284326</idno>
<idno type="pmid">32284326</idno>
<idno type="doi">10.1074/jbc.RA120.013679</idno>
<idno type="wicri:Area/PubMed/Corpus">000184</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000184</idno>
<idno type="wicri:Area/PubMed/Curation">000184</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000184</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000262</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000262</idno>
<idno type="wicri:Area/Ncbi/Merge">003941</idno>
<idno type="wicri:Area/Ncbi/Curation">003941</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003941</idno>
<idno type="wicri:Area/Main/Merge">000314</idno>
<idno type="wicri:Area/Main/Curation">000314</idno>
<idno type="wicri:Area/Main/Exploration">000314</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.</title>
<author><name sortKey="Gordon, Calvin J" sort="Gordon, Calvin J" uniqKey="Gordon C" first="Calvin J" last="Gordon">Calvin J. Gordon</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Alberta</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Tchesnokov, Egor P" sort="Tchesnokov, Egor P" uniqKey="Tchesnokov E" first="Egor P" last="Tchesnokov">Egor P. Tchesnokov</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Alberta</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Woolner, Emma" sort="Woolner, Emma" uniqKey="Woolner E" first="Emma" last="Woolner">Emma Woolner</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Alberta</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Perry, Jason K" sort="Perry, Jason K" uniqKey="Perry J" first="Jason K" last="Perry">Jason K. Perry</name>
<affiliation wicri:level="1"><nlm:affiliation>Gilead Sciences, Inc, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Gilead Sciences, Inc</wicri:regionArea>
<wicri:noRegion>Inc</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Feng, Joy Y" sort="Feng, Joy Y" uniqKey="Feng J" first="Joy Y" last="Feng">Joy Y. Feng</name>
<affiliation wicri:level="1"><nlm:affiliation>Biology, Gilead Sciences, Inc., United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Biology, Gilead Sciences, Inc.</wicri:regionArea>
<wicri:noRegion>Inc.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Porter, Danielle P" sort="Porter, Danielle P" uniqKey="Porter D" first="Danielle P" last="Porter">Danielle P. Porter</name>
<affiliation wicri:level="1"><nlm:affiliation>Gilead Scienes, Inc., United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Gilead Scienes, Inc.</wicri:regionArea>
<wicri:noRegion>Inc.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gotte, Matthias" sort="Gotte, Matthias" uniqKey="Gotte M" first="Matthias" last="Gotte">Matthias Gotte</name>
<affiliation wicri:level="1"><nlm:affiliation>Medical Microbiology and Immunology, University of Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Medical Microbiology and Immunology, University of Alberta</wicri:regionArea>
<wicri:noRegion>University of Alberta</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of biological chemistry</title>
<idno type="eISSN">1083-351X</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analogue remdesivir (RDV). RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus (EBOV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain-termination is RDV's plausible mechanism of action. Here, we expressed and purified active SARS-CoV-2 RdRp composed of the non-structural proteins nsp8 and nsp12. Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA. Incorporation of RDV-TP at position i caused termination of RNA synthesis at position i+3. We obtained almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps. A unique property of RDV-TP is its high selectivity over incorporation of its natural nucleotide counterpart ATP. In this regard, the triphosphate forms of 2'-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits. Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by the distantly related Lassa virus RdRp, and termination of RNA synthesis was not observed. These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral (DAA).</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>États-Unis</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Gordon, Calvin J" sort="Gordon, Calvin J" uniqKey="Gordon C" first="Calvin J" last="Gordon">Calvin J. Gordon</name>
</noRegion>
<name sortKey="Gotte, Matthias" sort="Gotte, Matthias" uniqKey="Gotte M" first="Matthias" last="Gotte">Matthias Gotte</name>
<name sortKey="Tchesnokov, Egor P" sort="Tchesnokov, Egor P" uniqKey="Tchesnokov E" first="Egor P" last="Tchesnokov">Egor P. Tchesnokov</name>
<name sortKey="Woolner, Emma" sort="Woolner, Emma" uniqKey="Woolner E" first="Emma" last="Woolner">Emma Woolner</name>
</country>
<country name="États-Unis"><noRegion><name sortKey="Perry, Jason K" sort="Perry, Jason K" uniqKey="Perry J" first="Jason K" last="Perry">Jason K. Perry</name>
</noRegion>
<name sortKey="Feng, Joy Y" sort="Feng, Joy Y" uniqKey="Feng J" first="Joy Y" last="Feng">Joy Y. Feng</name>
<name sortKey="Porter, Danielle P" sort="Porter, Danielle P" uniqKey="Porter D" first="Danielle P" last="Porter">Danielle P. Porter</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000314 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000314 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:32284326 |texte= Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32284326" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |